Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit and Q50 compressor; and disposable products comprising single-use disposables and nasal interfaces. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone603-658-0411
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$42.38 million
Profitability
Miscellaneous
Employees276
Next Earnings Date3/4/2020 (Confirmed)
OptionableNot Optionable
Vapotherm (NYSE:VAPO) Frequently Asked Questions
What is Vapotherm's stock symbol?
Vapotherm trades on the New York Stock Exchange (NYSE) under the ticker symbol "VAPO."
How were Vapotherm's earnings last quarter?
Vapotherm Inc (NYSE:VAPO) issued its quarterly earnings data on Tuesday, November, 5th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.11. The business earned $10.81 million during the quarter, compared to analysts' expectations of $11.10 million. Vapotherm had a negative net margin of 110.06% and a negative return on equity of 107.95%. View Vapotherm's Earnings History.
When is Vapotherm's next earnings date?
How can I listen to Vapotherm's earnings call?
Vapotherm will be holding an earnings conference call on Wednesday, March 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Vapotherm issued on next quarter's earnings?
Vapotherm issued an update on its fourth quarter 2019
Pre-Market earnings guidance on Friday, January, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $12.9-12.9 million, compared to the consensus revenue estimate of $12.39 million.
What price target have analysts set for VAPO?
1 Wall Street analysts have issued twelve-month price objectives for Vapotherm's shares. Their forecasts range from $27.00 to $27.00. On average, they expect Vapotherm's stock price to reach $27.00 in the next year. This suggests a possible upside of 187.2% from the stock's current price. View Analyst Price Targets for Vapotherm.
What is the consensus analysts' recommendation for Vapotherm?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vapotherm in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vapotherm.
Has Vapotherm been receiving favorable news coverage?
News articles about VAPO stock have trended somewhat positive recently, according to InfoTrie. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Vapotherm earned a coverage optimism score of 1.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Vapotherm.
Who are some of Vapotherm's key competitors?
Some companies that are related to Vapotherm include Intersect ENT (XENT), Orthofix Medical (OFIX), Orthopediatrics (KIDS), Cerus (CERS), LeMaitre Vascular (LMAT), Anika Therapeutics (ANIK), Antares Pharma (ATRS), SurModics (SRDX), SI-Bone (SIBN), AngioDynamics (ANGO), OraSure Technologies (OSUR), Inovio Pharmaceuticals (INO), Alphatec (ATEC), MiMedx Group (MDXG) and Utah Medical Products (UTMD).
What other stocks do shareholders of Vapotherm own?
Who are Vapotherm's key executives?
Vapotherm's management team includes the folowing people:
- Mr. Joseph F. Army, CEO, Pres & Director (Age 55)
- Mr. William Niland, Founder
- Mr. John Landry, VP, CFO, Sec. & Treasurer (Age 47)
- Mr. John Coolidge, VP of Operations (Age 58)
- Mr. Anthony Ten Haagen, VP of Legal & Compliance
When did Vapotherm IPO?
(VAPO) raised $60 million in an initial public offering (IPO) on Wednesday, November 14th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch and William Blair acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.
Who are Vapotherm's major shareholders?
Vapotherm's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (8.27%), Broadfin Capital LLC (4.76%), Driehaus Capital Management LLC (1.83%), Taylor Frigon Capital Management LLC (1.22%), State Street Corp (1.01%) and Geode Capital Management LLC (0.89%). Company insiders that own Vapotherm stock include Anthony L Arnerich, Elizabeth H Weatherman, Healthcare Holding BV Gilde, James W Liken, John Landry, Joseph Army and Michael Mcqueen. View Institutional Ownership Trends for Vapotherm.
Which major investors are selling Vapotherm stock?
VAPO stock was sold by a variety of institutional investors in the last quarter, including Alambic Investment Management L.P., Perceptive Advisors LLC and Bank of America Corp DE. View Insider Buying and Selling for Vapotherm.
Which major investors are buying Vapotherm stock?
VAPO stock was bought by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Taylor Frigon Capital Management LLC, Goldman Sachs Group Inc., Geode Capital Management LLC, State Street Corp, Cambridge Investment Research Advisors Inc., Spark Investment Management LLC and BCJ Capital Management LLC. Company insiders that have bought Vapotherm stock in the last two years include Anthony L Arnerich, Elizabeth H Weatherman, Healthcare Holding BV Gilde, James W Liken, John Landry, Joseph Army and Michael Mcqueen. View Insider Buying and Selling for Vapotherm.
How do I buy shares of Vapotherm?
Shares of VAPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Vapotherm's stock price today?
One share of VAPO stock can currently be purchased for approximately $9.40.
How big of a company is Vapotherm?
Vapotherm has a market capitalization of $198.19 million and generates $42.38 million in revenue each year. The company earns $-42,470,000.00 in net income (profit) each year or ($13.83) on an earnings per share basis. Vapotherm employs 276 workers across the globe.View Additional Information About Vapotherm.
What is Vapotherm's official website?
How can I contact Vapotherm?
Vapotherm's mailing address is 100 DOMAIN DRIVE, EXETER NH, 03833. The company can be reached via phone at 603-658-0411 or via email at [email protected]
MarketBeat Community Rating for Vapotherm (NYSE VAPO)
MarketBeat's community ratings are surveys of what our community members think about Vapotherm and other stocks. Vote "Outperform" if you believe VAPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VAPO will underperform the S&P 500 over the long term. You may vote once every thirty days.
